CYPJ promotes TAMs repolarization towards the M1 phenotype by inhibiting the activity of AKT1 and enhancing the innate and adaptive immune responses (Figure 7D), thereby facilitating the killing of tumor cells, which sheds light on the potential development of macrophage therapies for LIHC. The gene discussed is AKT1; the disease is neoplasm.